In a phase I/II clinical trial, epidermal growth factor receptor (EGFR)-targeted NIR-PIT was found to be safe and effective against unresectable or recurrent head and neck squamous cell carcinoma [27, 28]. Here, EGFR is linked to head and neck squamous cell carcinoma.